New Drug Promises Relief for Uveitis Patients
Uveitis is known to be a very painful condition that causes severe inflammation in the middle layer of the eyeball. There are many conventional treatments for this disease, beginning with an action as simple as using anti-inflammation eye drops to performing eye surgery in very extreme cases.
In June of 2016, an immune-suppressing drug, Humiria, has received approval to treat uveitis. This drug has been known to provide relief from the burning sensation as a result of inflammation. Although it does not cure uveitis, it is a great relief to many people who experience this condition [1]. According to the lead researcher, Dr. Glen Jaffe, this is the first drug to relieve symptoms of uveitis in FDA history that does not contain steroids [1]. In addition, this drug is able to block the proteins that are the primary cause of the inflammation caused in the eye.
Although the drug does not work towards the treatment of the condition it allows the patient to have some relief when curing the condition with additional medication.
Author
Dr. Paul Zickler is a graduate of the University of Wester Ontario in 1972. After graduating from the faculty of medicine, Dr. Zickler practiced as an Emergency Physician for 18 years. He has then operated ambulatory medical and travel clinics for 12 years. Dr. Zickler has become an Associate Professor of Emergency Medicine at the University of British Columbia, a Director of Professional Programs for the Justice Institute of British Columbia (paramedic academy), a principal investigator for Phase 2 and 3 studies researching vaccines, and a founding member of the Canadian International Pharmacy Association. Dr. Zickler is passionate about combining western prescription medicine and natural medicines.